

Accelaron Pharma Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 05-Aug-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 12

 Phase 2 Clinical..... 13

 Discovery..... 31

[Return to Table of Contents](#)

Acceleron Pharma Inc

COMPANY OVERVIEW

Company Name	Acceleron Pharma Inc
Parent Company Name	Acceleron Pharma Inc
Website	http://www.acceleronpharma.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	5
Number of Patents as Owner	42
Number of Patents as Third Party	1
Number of Deals	8
Key Indications	Anemia,Beta thalassemia,Sickle cell anemia,Muscle wasting disease,Ovary tumor,Cancer,Endometrioid carcinoma,Diamond Blackfan anemia,Fallopian tube cancer,Hepatocellular carcinoma,Metastatic renal cancer,Multiple myeloma,Myelofibrosis,Peritoneal tumor,Squamous cell carcinoma
Key Target-based Actions	TGF beta antagonist,Activin type-II receptor antagonist,GDF modulator,Activin type-IIB receptor antagonist,GDF-8 antagonist,Bone morphogenetic protein-11 ligand inhibitor,Immunoglobulin gamma Fc receptor agonist,Alk-1 protein kinase inhibitor,Bone morphogenetic protein-10 ligand modulator,Bone morphogenetic protein-9 ligand modulator
Key Technologies	Biological therapeutic,Protein fusion,Immunoglobulin-G,Antibody fragment,Subcutaneous formulation,Receptor fusion,Protein recombinant,Parenteral formulation unspecified,Protein chimeric,Small molecule therapeutic,Soluble receptor

COMPANY PROFILE

SUMMARY

Acceleron Pharma Inc, founded in 2003 and headquartered in Cambridge, MA, is a biopharmaceutical company developing novel protein therapeutics for cancer and rare diseases.

COMPANY LOCATION

In May 2009, Acceleron signed a lease on a third facility in Cambridge, MA. At that time, the company planned to increase its workforce by 50% in 2009.

In June 2008, the company announced that it was to double the size of its facilities in Cambridge, MA and increase its workforce by 40% during 2008.

LICENSING AGREEMENTS

In February 2008, as part of a codevelopment agreement for ACE-011, Acceleron and Celgene signed an option deal for the the development of three discovery programs in the field of osteoporosis and bone loss.

In August 2004, Artemis Pharmaceuticals GmbH and Acceleron signed a cooperation agreement in mouse genetics. Artemis would apply its ArteMice technology platforms to generate a specifically genetically engineered mouse model system for Acceleron, which would use the mouse model to develop drugs for the treatment of musculoskeletal and metabolic disorders.

EARLY R&D

By May 2007, the company was investigating a number of research programs including ACE-05X for bone loss, ACE-06X and ACE-07X for fat accumulation, and ACE-08X and ACE-07X for muscle loss.

FINANCIA

[Return to Table of Contents](#)



In January 2014, the company filed registration statement for a proposed public offering of common stock. Later that month, the company priced the offering of 2,400,000 shares of common stock at a price of \$50 per share. The underwriters were granted a 30-day option to buy up to an additional 360,000 shares of common stock. Later in January 2014, the offering closed, with full exercise of the underwriters' option. At that time, Acceleron had raised aggregate net proceeds of approximately \$129 million from the sale.

In December 2013, the company was selected for addition to the Russell 2000, Russell 3000 and Russell Global Indexes, and would join the indexes after the NASDAQ market closes on December 20, 2013.

In August 2013, Acceleron planned an IPO of its common stock. In September 2013, Acceleron priced its IPO of 5,580,000 shares of common stock at \$15.00 per share and granted the underwriters a 30-day option to purchase up to an additional 837,000 shares. Separately, in a concurrent, side-by-side private placement, Acceleron's collaboration partner, Celgene agreed to purchase 666,667 shares of common stock from Acceleron at the public offering price. Acceleron's stock has been approved for listing on the NASDAQ Global Market and was expected to begin trading under the ticker symbol "XLRN" on September 19, 2013. The IPO closed in September 2013. At that time, underwriters exercised in full option to purchase shares and the company raised gross proceeds of \$106.3 million. Net proceeds from the offering were \$96.7 million.

In December 2011, Acceleron raised \$30 million from a private financing.

In October 2007, the company raised \$31 million from a series C financing round. At that time, Acceleron planned to use the proceeds to advance its clinical and preclinical pipeline.

By August 2006, Acceleron had obtained \$30 million in Series B financing. In May 2007, investors included Advanced Technology Ventures, OrbiMed Advisors, Polaris Venture Partners, Sutter Hill Investors and Venrock Associates.

In January 2006, the company received \$8 million in debt financing from Hercules Technology Growth Capital.

In February 2004, Acceleron raised \$25 million in its first round of private equity financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)

Drugs by Indication Table


Indication	Active	Inactive	Total
Musculoskeletal disease	1	6	7
Hematological disease	2	2	4
Genetic disorder	2	1	3
Growth disorder	1	2	3
Metabolic disorder	0	2	2
Inflammatory disease	0	2	2
Immune disorder	0	2	2
Neurological disease	0	1	1
Ocular disease	0	1	1
Injury	0	1	1
Nutritional disorder	0	1	1
Dermatological disease	1	0	1
Genitourinary disease	1	0	1
Neoplasm	1	0	1
Gynecology and obstetrics	1	0	1
Endocrine disease	1	0	1
Gastrointestinal disease	1	0	1

[Return to Table of Contents](#)



Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	3
Discovery	1
Discontinued	1
No Development Reported	4

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	3	0	0	0	3
Technology - Other Proprietary	0	0	2	0	2
Drug - Development/Commercialization License	1	0	0	0	2
Technology - Delivery/Formulation	1	0	0	0	1

[Return to Table of Contents](#)

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	3	9
Endocrine disease	1	6
Hematological disease	3	6
Musculoskeletal disease	0	5
Gynecology and obstetrics	1	4
Genitourinary disease	2	3
Gastrointestinal disease	2	2
Immune disorder	0	2
Degeneration	0	2
Neurological disease	0	2
Growth disorder	0	2
Genetic disorder	1	1
Dermatological disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	6	12
Phase 1	0	6
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	13	0	13

[Return to Table of Contents](#)



Endocrine disease	24	0	24
Gastrointestinal disease	15	2	17
Genitourinary disease	5	0	5
Growth disorder	13	0	13
Hematological disease	17	0	17
Degeneration	9	0	9
Andrology	1	0	1
Immune disorder	17	2	19
Psychiatric disorder	1	0	1
Musculoskeletal disease	30	0	30
Neoplasm	22	0	22
Ocular disease	3	0	3
Genetic disorder	2	0	2
Metabolic disorder	11	0	11
Mouth disease	1	0	1
Neurological disease	11	0	11
Nutritional disorder	11	0	11
Prophylaxis	1	0	1
Respiratory disease	5	0	5
Infectious disease	4	0	4
Injury	7	0	7
Toxicity and intoxication	1	0	1
Inflammatory disease	11	1	12
Gynecology and obstetrics	8	0	8
Dermatological disease	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

sotatercept

sotatercept SNAPSHOT

Drug Name	sotatercept
Key Synonyms	sotatercept
Originator Company	Acceleron Pharma Inc
Active Companies	Acceleron Pharma Inc;Celgene Corp
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Myelofibrosis;Beta thalassemia;Anemia;Sickle cell anemia;Diamond Blackfan anemia
Target-based Actions	Bone morphogenetic protein-11 ligand inhibitor;Activin type-II receptor antagonist
Other Actions	Hematopoietic stimulant;Bone resorption inhibitor;Osteoblast modulator;Synergist
Technologies	Antibody fragment;Immunoglobulin-G;Subcutaneous formulation;Biological therapeutic;Protein chimeric;Soluble receptor
Last Change Date	24-Jul-2014

sotatercept DEVELOPMENT PROFILE

SUMMARY

Acceleron and Celgene are developing sotatercept (ACE-011, ACE-011d, RAP-011, ActRIIA-IgG1), a fusion protein containing a soluble form of the activin IIa receptor that inhibits signalling of the receptor and an Fc fragment of IgG1, for the potential treatment of anemia caused by beta-thalassemia, myelodysplastic syndrome (MDS), diamond blackfan, myelofibrosis and chronic kidney disease ,,. In December 2013, the companies are also investigating the drug for the potential treatment of sickle cell anemia. In November 2012, a phase II trial began for the treatment of anemia in patients with MDS ; in February 2014, interim data were expected in the first half of 2014. In March 2012, phase IIa trial began in patients with red blood cell transfusion-dependent beta-thalassemia ; in February 2014, interim data were expected in the first half of 2014. By July 2010, a phase II trial for renal anemia had been initiated ; in January 2013, the trial was ongoing ; in February 2014, interim data were expected in the first half of 2014. In January 2012, an investigator-led phase I/II trial in patients with red blood cell transfusion-dependent Diamond-Blackfan anemia was initiated ; in October 2012, Celgene listed Diamond-Blackfan anemia on its development pipeline. In June 2013, the drug was listed as being in phase II for myelofibrosis. In December 2013, a registration enabling study was planned to be initiated by the end of 2014 or in the beginning of 2015.

The drug is also being developed in anemia of malignancy; a phase II trial began in solid tumor patients not undergoing chemotherapy in June 2010, which was ongoing in March 2013.

[Return to Table of Contents](#)

Development was previously undertaken for chemotherapy-induced anemia. In July 2009, a phase II trial in chemotherapy-treated breast cancer patients was initiated and in February 2011, a phase II/III trial in chemotherapy-treated non-small-cell lung cancer (NSCLC) patients was initiated. However both trials were subsequently terminated due to low recruitment, and the indication no longer appears on the companies' pipeline. In October 2008, a phase II trial for multiple myeloma-associated bone loss was initiated, which was completed in October 2009; by March 2013, no further development had been reported.

sotatercept DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Acceleron Pharma Inc	Anemia	US	Phase 2 Clinical	28-Jul-2009
Acceleron Pharma Inc	Beta thalassemia	France	Phase 2 Clinical	31-May-2012
Acceleron Pharma Inc	Diamond Blackfan anemia	US	Phase 2 Clinical	25-Oct-2012
Acceleron Pharma Inc	Myelofibrosis	US	Phase 2 Clinical	18-Jun-2013
Celgene Corp	Anemia	France	Phase 2 Clinical	30-Nov-2012
Celgene Corp	Anemia	US	Phase 2 Clinical	28-Jul-2009
Celgene Corp	Beta thalassemia	France	Phase 2 Clinical	31-May-2012
Celgene Corp	Diamond Blackfan anemia	US	Phase 2 Clinical	25-Oct-2012
Celgene Corp	Myelofibrosis	US	Phase 2 Clinical	18-Jun-2013
Acceleron Pharma Inc	Sickle cell anemia	US	Discovery	03-Dec-2013
Celgene Corp	Beta thalassemia	US	Discovery	05-Dec-2013
Celgene Corp	Sickle cell anemia	US	Discovery	03-Dec-2013
Acceleron Pharma Inc	Bone resorption	US	No Development Reported	07-Mar-2013
Celgene Corp	Bone resorption	US	No Development Reported	07-Mar-2013

[Return to Table of Contents](#)



sotatercept DRUG NAMES

Names	Type
bone loss therapy, Acceleron	
sotatercept	USAN, INN
RAP-011	Research Code
activin IIa receptor antagonist (anemia, bone loss), Acceleron	
ACE-011d	Research Code
ACE-011	Research Code
ActRIIA-IgG1	

sotatercept CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Anemia											
0	0	0	0	4	6	0	0	0	0	4	6
Multiple myeloma											
0	0	0	0	0	1	1	1	0	0	1	2
Osteoporosis											
0	0	0	0	0	0	0	2	0	0	0	2
Myeloproliferative disorder											
0	0	0	0	1	1	0	0	0	0	1	1
Diamond Blackfan anemia											
0	0	0	0	0	0	1	1	0	0	1	1
Myelofibrosis											
0	0	0	0	1	1	0	0	0	0	1	1
Beta thalassemia											
0	0	0	0	0	1	0	0	0	0	0	1

[Return to Table of Contents](#)

Metastatic breast cancer											
0	0	0	0	0	1	0	0	0	0	0	1
Solid tumor											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	4	9	2	4	0	0	6	13

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

sotatercept DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Acceleron Pharma Inc	2	0	1	0	3
Celgene Corp	0	0	1	0	1
The Salk Institute for Biological Studies	1	0	0	0	1
Multiple Myeloma Research Foundation	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1
Drug - Development/Commercialization License	1	0	1
Drug - Funding	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Acceleron Pharma Inc	12	0	12
Alkermes plc	3	0	3
Celgene Corp	3	0	3
Shire plc	1	0	1
Individual	1	0	1
Childrens Hospital of Philadelphia	1	0	1
University of Washington	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	13
Product	3

[Return to Table of Contents](#)

dalantercept

dalantercept SNAPSHOT

Drug Name	dalantercept
Key Synonyms	dalantercept
Originator Company	Acceleron Pharma Inc
Active Companies	Acceleron Pharma Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Peritoneal tumor;Squamous cell carcinoma;Fallopian tube cancer;Endometrioid carcinoma;Hepatocellular carcinoma;Ovary tumor;Metastatic renal cancer
Target-based Actions	Bone morphogenetic protein-10 ligand modulator;Alk-1 protein kinase inhibitor;Bone morphogenetic protein-9 ligand modulator;TGF beta antagonist
Other Actions	Anticancer;Angiogenesis inhibitor;Anticancer protein kinase inhibitor;Ocular antineovascularisation agent
Technologies	Antibody fragment;Receptor fusion;Subcutaneous formulation;Biological therapeutic;Protein chimeric;Protein fusion
Last Change Date	11-Jul-2014

dalantercept DEVELOPMENT PROFILE

SUMMARY

Acceleron is developing dalantercept (ACE-041, RAP-041), a chimeric protein consisting of a soluble activin receptor-like kinase 1 (ALK1) receptor with an Fc receptor, which inhibits angiogenesis by preventing the interaction of members of the TGFbeta protein superfamily (BMP9 and BMP10) with ALK1 to prevent signalling through the ALK1 receptor, for the potential sc treatment of squamous cell carcinoma, metastatic renal cell carcinoma, ovarian cancer, fallopian tube and primary peritoneal carcinoma,, , ,,. In December 2013, the company is also investigating dalantercept for the potential treatment of hepatocellular cancer (HCC). In October 2011, a phase II trial in patients with squamous cell carcinoma of the head and neck (SCCHN) began. In November 2012, a phase II study was initiated in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and at that time, the study was expected to complete in October 2015. In December 2012, a phase II study in patients with metastatic renal cell carcinoma was initiated and at that time, the study was expected to complete in December 2018; in November 2013, enrollment was completed for the dose-escalation stage. In July 2014, a phase II trial for HCC was planned to be initiated in the third quarter of 2014. In October 2009, a phase I trial began in patients with solid tumors or multiple myeloma. In February 2014, the company expected to initiate clinical trials in additional cancer including colorectal and brain cancer in the second half of 2014.

The company was previously developing the drug for the treatment of endometrial cancer,, , ,,. In September 2012, a phase II trial in endometrial cancer was initiated ; however by December 2013, dalantercept had shown no sufficient activity to warrant development as a monotherapy for endometrial cancer and will not advance to the second stage of this trial.

[Return to Table of Contents](#)



The company was previously investigating the drug for the treatment of age-related macular degeneration (AMD), solid tumors, multiple myeloma. In September 2011, the drug was listed as being in phase I development for AMD, solid tumors and multiple myeloma ; however in June 2013, the indications were no longer listed on the current pipeline.

The company was previously investigating the drug for arthritis,. However, no further development was reported for this indication since May 2006.

dalantercept DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Acceleron Pharma Inc	Fallopian tube cancer	US	Phase 2 Clinical	30-Nov-2012
Acceleron Pharma Inc	Metastatic renal cancer	US	Phase 2 Clinical	31-Dec-2012
Acceleron Pharma Inc	Ovary tumor	US	Phase 2 Clinical	30-Nov-2012
Acceleron Pharma Inc	Peritoneal tumor	US	Phase 2 Clinical	30-Nov-2012
Acceleron Pharma Inc	Squamous cell carcinoma	US	Phase 2 Clinical	21-Oct-2011
Acceleron Pharma Inc	Hepatocellular carcinoma	US	Discovery	03-Dec-2013
Acceleron Pharma Inc	Endometrioid carcinoma	US	Suspended	22-Nov-2013
Acceleron Pharma Inc	Age related macular degeneration	US	No Development Reported	18-Jun-2013
Acceleron Pharma Inc	Arthritis	US	No Development Reported	16-Nov-2007
Acceleron Pharma Inc	Multiple myeloma	US	No Development Reported	18-Jun-2013
Acceleron Pharma Inc	Solid tumor	US	No Development Reported	18-Jun-2013

dalantercept DRUG NAMES

Names	Type
dalantercept	USAN, INN
ACE-041	Research Code
chimeric receptor TGF beta antagonist (sc, solid tumors/multiple myeloma/AMD), Acceleron	
recombinant ALK-1 signaling inhibitor (angiogenesis), Acceleron	
Alk1-Fc	
RAP-041	Research Code

[Return to Table of Contents](#)

dalantercept CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Peritoneal tumor											
0	0	0	0	1	1	0	0	0	0	1	1
Hepatocellular carcinoma											
0	0	0	0	1	1	0	0	0	0	1	1
Ovary tumor											
0	0	0	0	1	1	0	0	0	0	1	1
Fallopian tube cancer											
0	0	0	0	1	1	0	0	0	0	1	1
Renal cell carcinoma											
0	0	0	0	1	1	0	0	0	0	1	1
Squamous cell carcinoma											
0	0	0	0	0	1	0	0	0	0	0	1
Metastatic head and neck cancer											
0	0	0	0	0	1	0	0	0	0	0	1
Endometrioid carcinoma											
0	0	0	0	0	1	0	0	0	0	0	1
Advanced solid tumor											
0	0	0	0	0	0	0	1	0	0	0	1
Multiple myeloma											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	3	5	0	1	0	0	3	6

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

dalantercept DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




[Return to Table of Contents](#)

Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Accelaron Pharma Inc	4	0	4
Alkermes plc	1	0	1
Ludwig Institute for Cancer Research	1	0	1
Individual	1	0	1
Delaware Capital Formation Inc	1	0	1

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	2
Analyte	1
New use	1
Formulation	1

[Return to Table of Contents](#)

luspatercept

luspatercept SNAPSHOT

Drug Name	luspatercept
Key Synonyms	luspatercept
Originator Company	Acceleron Pharma Inc
Active Companies	Celgene Corp;Acceleron Pharma Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Beta thalassemia;Sickle cell anemia;Anemia
Target-based Actions	TGF beta antagonist;TGF beta ligand inhibitor;GDF modulator
Other Actions	Anticancer;Hematopoietic stimulant
Technologies	Antibody fragment;Receptor fusion;Immunoglobulin-G;Subcutaneous formulation;Biological therapeutic;Protein fusion;Protein recombinant;Soluble receptor
Last Change Date	14-Jul-2014

luspatercept DEVELOPMENT PROFILE

SUMMARY

Acceleron Pharma, in collaboration with Celgene, is developing luspatercept (ACE-536, ACE-536d), a growth and differentiation factor (GDF) protein-based therapy and a soluble receptor fusion protein consisting of a modified human activin receptor type-IIb extracellular domain linked to a human IgG1 Fc domain, that modulates GDF ligands and receptors, and selectively increases red blood cells and hemoglobin by inhibiting TGF beta protein superfamily members, for the potential treatment of anemia associated with myelodysplastic syndrome and beta thalassemia,,,. In December 2013, the companies are also investigating the drug for the potential treatment of sickle cell anemia. In January 2013, a phase II trial for beta-thalassemia was initiated in Italy ; by February 2014, interim data had been reported. In January 2013, a phase II trial was initiated in Germany for the treatment of anemia in patients with myelodysplastic syndrome; in February 2014, interim data were expected in June 2014. In December 2013, a registration enabling study was planned to be initiated by the end of 2014 or in the beginning of 2015.

luspatercept DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Acceleron Pharma Inc	Anemia	Germany	Phase 2 Clinical	17-Jan-2013
Acceleron Pharma Inc	Beta thalassemia	Italy	Phase 2 Clinical	11-Jan-2013
Celgene Corp	Anemia	Germany	Phase 2 Clinical	17-Jan-2013
Celgene Corp	Beta thalassemia	Italy	Phase 2 Clinical	11-Jan-2013

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Acceleron Pharma Inc	Beta thalassemia	US	Discovery	11-Mar-2013
Acceleron Pharma Inc	Sickle cell anemia	US	Discovery	03-Dec-2013
Celgene Corp	Beta thalassemia	US	Discovery	11-Mar-2013
Celgene Corp	Sickle cell anemia	US	Discovery	03-Dec-2013

luspatercept DRUG NAMES

Names	Type
RAP-536	Research Code
growth and differentiation factor (GDF) protein-based therapy (anemia associated with myelodysplastic syndrome), Acceleron luspatercept	USAN, PINN
ACE-536	Research Code
Anemia therapy, Acceleron	
GDF ligands and receptors modulator (anemia), Acceleron	
ACE-536d	Research Code
GDF ligands and receptors modulator (anemia associated with myelodysplastic syndrome), Acceleron/ Celgene	

luspatercept CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Beta thalassemia											
0	0	0	0	1	1	0	0	0	0	1	1
Anemia											
0	0	0	0	1	1	0	0	0	0	1	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	2	2	0	1	0	0	2	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

Iuspatercept DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Celgene Corp	0	0	1	0	1
Acceleron Pharma Inc	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Acceleron Pharma Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1

ACE-083

ACE-083 SNAPSHOT

Drug Name	ACE-083
Key Synonyms	
Originator Company	Acceleron Pharma Inc
Active Companies	Acceleron Pharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Muscle wasting disease
Target-based Actions	TGF beta antagonist
Other Actions	
Technologies	Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
Last Change Date	12-Jul-2014

ACE-083 DEVELOPMENT PROFILE

SUMMARY

Acceleron is investigating a locally acting engineered protein therapeutic, ACE-083, which acts by inhibiting TGF-beta protein, for the potential treatment of muscle wasting disease by increasing muscle mass and strength. In November 2013, preclinical activities were ongoing, in preparation for the submission of an IND in 2014 ; in July 2014, phase I development was planned to be initiated in the fourth quarter of 2014.

ACE-083 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Acceleron Pharma Inc	Muscle wasting disease	US	Discovery	06-Nov-2013

ACE-083 DRUG NAMES

Names	Type
TGF-beta inhibitor (muscle weakness), Acceleron Pharma	
ACE-083	Research Code

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

